Introduction {#Sec1}
============

Elevated blood pressure (BP) or hypertension has become one of the biggest single contributors to the global burden of disease and global mortality \[[@CR1]\]. Hypertension causes the premature death of over 9.4 million people worldwide every year according to a 23-year-long systemic analysis \[[@CR2]\], and was responsible for approximately 10.4 million deaths in 2013 \[[@CR3]\]. At the start of this century, it was estimated that nearly 972 million people worldwide had hypertension, and it was predicted that the prevalence would increase to over 1.56 billion by 2025 \[[@CR4]\]. The prevalence of hypertension among people aged 35--64 years in the US population is about 30% \[[@CR5]\] and about 44% in European countries \[[@CR6]\]. Moreover, hypertension continues to be undertreated \[[@CR7], [@CR8]\].

The chief aim of the diagnosis and treatment of hypertension is to reduce death and morbidity from cardiovascular disease \[[@CR9]\] (see Fig. [1](#Fig1){ref-type="fig"}). With optimum control of BP, it is possible to prevent damage to many organ systems, and the treatment of underlying vascular diseases is also an important management objective \[[@CR10]\]. Achieving BP goals is a persistent challenge for hypertensive patients with low to moderate risk, and reaching the figure of 130/80 mmHg is a goal for high-risk patients, such as those with diabetes, cardiovascular disease, or renal disease \[[@CR11]\]. The guidelines for the management of hypertension in the United States, Europe, and Japan recommend considering a combination of two drugs at the beginning of treatment in high-risk patients or those with grades 2--3 hypertension \[[@CR12]--[@CR14]\]. Therefore, in clinical practice, two or more drugs with different mechanisms of action are often chosen, and are considered to have a better prospect to achieve satisfactory BP control. Olmesartan is classified as an angiotensin receptor blocker (ARB).Fig. 1Major compliances of hypertension

Methods {#Sec2}
=======

The literature searches were conducted in March to April 2016 using PubMed and Excerpta Medica Database (EMBASE) together with the Web of Science database. We selected influential randomized controlled trials in the field of hypertension research. In brief, we used keywords such as olmesartan medoxomil monotherapy, or versus placebo or antihypertensive mono or combination therapy (trial duration at least 2 months). We included trials with drugs in adults, men, and non-pregnant women, with uncomplicated primary hypertension. Trials that had oral antihypertensive treatment with other angiotensin II receptor blockers (ARBs), thiazide and thiazide-like diuretics, calcium-channel blockers and angiotensin-converting enzyme inhibitors (ACEI), as comparators, were eligible for inclusion. The contents of this article are based on previously published studies and do not involve any new studies of human or animal subjects performed by any of the authors.

Discovery and Development of Angiotensin Receptor Blockers {#Sec3}
----------------------------------------------------------

In 1898, the physiologist Robert Tigerstedt and his student, Per Bergman, working at the Karolinska Institute in Stockholm, Sweden, injected rabbits with different kinds of kidney extracts, and found some caused a rise in blood pressure \[[@CR15]\]. They named the active principle "renin", and suggested it was a protein due to its water-soluble, non-dialyzable, and heat-labile properties. However, this remarkable discovery remained largely unexplored for almost 40 years. In the 1930s, Harry Goldblatt conducted experiments in which he constricted the blood flow to the kidneys in dogs, and found that ischemia caused the kidneys to secrete a substance that caused vasoconstriction \[[@CR16]\]. Although initially it was thought that this substance was the same as the renin discovered by Tigerstedt, attempts to purify it produced less hypertensive activity, rather than the higher activity that was expected. In 1939, renin itself was found not to cause the rise in blood pressure, but rather was an enzyme that catalyzed the formation of another substance that actually was responsible, initially named "angiotonin" and "hypertensin", and then the compromise name "angiotensin" was agreed. It was found that renin acts on a serum α2-globulin produced by the liver called angiotensinogen, which has 453 amino acids. The cleavage product is a small peptide called angiotensin I (Ang I), which has ten amino acids, and is cleaved by angiotensin-converting enzyme (ACE) to form the eight-amino-acid angiotensin II (Ang II, Asp-Arg-Val-Tyr-Ile-His-Pro-Phe). The most important receptor for Ang II is called angiotensin II receptor type 1 or (AT~1~).

In the 1970s, it was found that Ang II raised BP, and individuals with high levels of renin activity in plasma were at increased risk of cardiovascular disease \[[@CR17]\]. The physiological functions of angiotensin II in the cardiovascular system have been fully explained and presented in various review articles \[[@CR18]--[@CR21]\]. The major actions of Ang II include potent vasoconstriction effects of arterioles throughout the body; decreased renal blood flow and increased tubular sodium reabsorption and water retention. Ang II stimulates aldosterone and anti-diuretic hormone (ADH) secretion via the hypothalamus pituitary-adrenal axis or the local system (Fig. [2](#Fig2){ref-type="fig"}). With the introduction of ACE inhibitors such as captopril in the late 1970s \[[@CR22]\], it was confirmed that pharmaceuticals that reduce Ang II activity could treat hypertension.Fig. 2The mechanism of ACEI and ARB function in the RAS system

The first attempts to develop useful Ang II receptor (AT~1~) antagonists focused on angiotensin peptide analogs. Saralasin contains amino acid replacements by sarcosine, valine, and alanine (Sar-Arg-Val-Tyr-Val-His-Pro-Ala) and is a partial agonist of the Ang II receptor \[[@CR23]\].

In the early 1980s it was found that some imidazole-5-acetic acid derivatives diminished blood pressure rise after administration of Ang II in rats \[[@CR24]\]. Two compounds, S-8307 and S-8308, were later found to be promising non-peptide Ang II receptor antagonists. Structural modifications were made, and the orally active, potent, and selective nonpeptide AT~1~ receptor blocker losartan was developed. In 1995 losartan was approved for clinical use in the US, and since then seven additional "sartans" have been approved (irbesartan, olmesartan, candesartan, valsartan, fimasartan, eprosartan, and azilsartan) \[[@CR25]\]. Three of these sartans (olmesartan, azilsartan, and candesartan) are usually administered as ester prodrugs. The goal of using an ester prodrug is to improve on the ADME (absorption, distribution, metabolism, excretion) properties of the drug. In the case of olmesartan and azilsartan the prodrug moiety is medoxomil (5-methyl-2-oxo-1,3-dioxol-4-yl)-methyl ester. olmesartan medoxomil is hydrolyzed by several esterase enzymes in the intestines releasing the active drug, olmesartan, which is easily absorbed \[[@CR26]\].

Choice of Medications for Hypertension {#Sec4}
--------------------------------------

The first-choice of medication to be employed for primary hypertension patients with additional complications such as heart failure, coronary artery disease, and diabetes mellitus, etc., are ACEI; this is accordance with guidelines recommended by several medical societies. However, since ACEI drugs inhibit ACE, which also degrades bradykinin, bradykinin therefore accumulates and can cause angioedema or angioneurotic edema. This is a rapid swelling of the dermis, subcutaneous tissue, mucosa, and submucosal tissues (similar to an allergic reaction) and can be life-threatening due to airway blockage (Table [1](#Tab1){ref-type="table"}).Table 1Introductions of different sartan-type medicationsMedicationsStructureFDA-approved dateDaily dosage (mg, starting/maximal)PharmacokineticsSide effectsReferencesBioavailability (%)Protein binding rate (%)Active metaboliteHalf-life (h)Excretion (%)Losartan![](40119_2017_87_Figa_HTML.gif){#d29e501}1995/4/1450/1003398EXP31746--9^a^Renal 50 Biliary 50Dizziness (0.3%)\
Hepatic dysfunction (0.2%)\
Headache (0.2%)\
Anemia (0.2%)\
Cough (0.2%)\[[@CR101]\]Valsartan![](40119_2017_87_Figb_HTML.gif){#d29e552}1996/12/2380/1602595No9Renal 30 Biliary 70Headache (5.5%)\
Dizziness (3.1%)\
Nasopharyngitis (2.0%)\
Diarrhea (1.2%)\[[@CR102]\]Candesartan cilexetil![](40119_2017_87_Figc_HTML.gif){#d29e598}1998/6/44/324299.5Candesartan3.5--11Renal 60 Biliary 40Headache (3.2%)\
Back pain (3.0%)\
Dizziness (2.6%)\
Upper respiratory tract infection (2.5%)\
Cough (1.6%)\[[@CR103]\]Irbesartan![](40119_2017_87_Figd_HTML.gif){#d29e646}1997/9/30150/3007090No11--15Renal 20 Biliary 80Dizziness (3.8%)\
Headache (3.8%)\[[@CR104]\] \[[@CR105]\]Eprosartan![](40119_2017_87_Fige_HTML.gif){#d29e691}1997/12/22300/12001398No5--9Renal 10 Biliary 90Headache (10%)\
Upper respiratory tract\
infection (8%)\
Myalgia (4%)\
Cough (3.5%)\[[@CR106]\] \[[@CR107]\]Telmisartan![](40119_2017_87_Figf_HTML.gif){#d29e742}1998/11/1040/8043\>99No24Biliary 98Headache (4.4%)\
Dizziness (2.4%)\
Series of respiratory infection (8.0%)\
Pain (1.3%)\[[@CR108]\] \[[@CR109]\]Olmesartan medoxomil![](40119_2017_87_Figg_HTML.gif){#d29e791}2002/4/2510/4026\>99Olmesartan12--15Renal 40 Biliary 60Headache (7.2%)\
Upper respiratory infections (4.9%)\
Dizziness (2.8%)\[[@CR110]\] \[[@CR111]\]Fimasartan![](40119_2017_87_Figh_HTML.gif){#d29e838}^a^20/4801995No5--16Biliary 97Dizziness (1.55%)\
Headache (0.52%)\[[@CR112]\] \[[@CR113]\]Azilsartan medoxomil![](40119_2017_87_Figi_HTML.gif){#d29e886}2011/2/2540/8058\>99Azilsartan11Renal 43 Biliary 57Dizziness (4%)\
Dyslipidemia (3.3%)\
Diarrhea (2%)\
Increased serum creatinine (0.2%)\[[@CR114]\]^a^This drug is not approved by US FDA at present

Sartans or ARBs are known for their excellent side-effect profiles, which have been shown to be similar to those of placebos in several clinical trials. Therefore, ARBs are used in some cases when patients who are not tolerant to ACEIs. ARBs can avert the incidence of this side effect, and thus can also achieve better efficacy in controlling BP. Previous studies suggested that in addition to the antihypertensive effect, the ARB might directly prevent organ damage \[[@CR27]\].

Mostly, the combination therapy choice with ARB for mild-to-severe hypertensive patients range from CCB to diuretics, which are two strongly effective and tolerable agents. Since there is no report of severe drug conflict among ARB, CCB, and diuretics, concomitant use of these anti-hypertensive that act through different pharmacological pathways is recommended for patients with moderate-to-severe hypertension and those who do not reach BP goals with monotherapy \[[@CR28]\].

Moreover, some clinical trials and meta-analyses that have recently been published have suggested that ARBs are not particularly effective in preventing cardiovascular events, like severe cardiovascular diseases (CVD), and may also have side effects such as adverse renal effects \[[@CR29]--[@CR36]\]. This controversy about the efficacy of ARBs in treating hypertension and preventing cardiovascular events emphasizes the necessity to select the best agents for each particular patient for BP control \[[@CR37]\]. Some studies have brought into question the use of ARBs for treating patients with severe CVD or preventing patients from developing CVD, because ARBs did not decrease the morbidity and mortality of the study patients \[[@CR38]--[@CR41]\]. For instance, one meta-analysis explored the efficacy of ARBs in the prevention of myocardial infarction and other cardiovascular outcomes. The results showed, when compared with placebo or active treatment, that ARBs were ineffective in the prevention of myocardial infarction (RR 0.99, 95% CI 0.92--1.07), death, cardiovascular death, or angina pectoris \[[@CR38]\]. Moreover, another meta-analysis investigated the efficacy of ACEI and ARB in the prevention of CVD in patients with diabetes and hypertension and revealed that ACEI could significantly reduce the risk of all-cause mortality by 13% (RR 0.87; 95% CI 0.78--0.98), incidence of cardiovascular deaths by 17% (0.83; 0.70--0.99), and major cardiovascular events by 14% (0.86; 0.77--0.95). However, ARB did not show the same advantages \[[@CR41]\].

Therefore, the choice of antihypertensive drugs significantly depends on the individual patients' medical condition. For patients with mild-to-moderate hypertension who are also intolerant to ACEI, ARB is a good choice for BP control. For patients with primary hypertension who are tolerant to ACEI and have CVD such as heart failure ACEI should be recommended due to the fact that ACEI has a better ability to protect renal function and prevent the incidence of CVD.

The Pharmacology of Olmesartan {#Sec5}
------------------------------

### Pharmacodynamics Properties of Olmesartan Medoxomil {#Sec6}

Olmesartan medoxomil is a white to light yellowish-white powder or crystalline powder with a molecular weight of 558.6, and practically insoluble in water and sparingly soluble in methanol \[[@CR42]\]. It is an angiotensin II type 1 receptor antagonist that inhibits the actions of angiotensin II on the renin--angiotensin--aldosterone system, which plays a key role in the pathogenesis of hypertension. Oral olmesartan, 10--40 mg once daily, is recommended for the treatment of adult patients with hypertension \[[@CR43]\]. Besides, olmesartan blocks the action of angiotensin II by binding with high selectivity to the angiotensin II type 1 receptor and not to angiotensin II type 2 receptor \[[@CR44]\]. It binds to the type 1 receptor with a high degree of insurmountability and with greater affinity than most other ARBs. According to studies in vivo, olmesartan dose-dependently antagonized the vasoconstrictor and pressure responses induced with angiotensin II \[[@CR45]\].

### Pharmacokinetics Properties of Olmesartan Medoxomil {#Sec7}

Olmesartan is rapidly and completely bio-activated by ester hydrolysis to olmesartan during absorption from the gastrointestinal tract. Olmesartan is rapidly absorbed following oral administration and is completely metabolized to the pharmacologically active metabolite. Steady-state levels are achieved within 3--5 days and no accumulation in plasma occurs with once-daily dosing. The absolute bioavailability of olmesartan is approximately 26%. After oral administration, the peak plasma concentration (*C* ~max~) of olmesartan can be reached after 1--2 h, and food does not affect the bioavailability of olmesartan. In addition, the volume of distribution is approximately 17 l. Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells \[[@CR46]\].

To our knowledge, olmesartan, as an orally administered prodrug, is able to rapid and complete converted into olmesartan during absorption, and is virtually no further metabolism of olmesartan \[[@CR47]\]. Total plasma clearance of olmesartan is 1.3 l/h, with a renal clearance of 0.6 l/h. No components other than olmesartan were detected in plasma following oral administration of radiolabeled olmesartan in healthy volunteers \[[@CR48]\]. Besides, *C* ~max~ of olmesartan increases linearly with single oral doses of olmesartan between 10 and 160 mg \[[@CR49]\]. Approximately 35--50% of the absorbed dose is recovered in urine while the remainder is eliminated in feces via the bile \[[@CR50]\].

The Clinical Use of Olmesartan Alone or in Combination {#Sec8}
------------------------------------------------------

### Monotherapy of Olmesartan {#Sec9}

The open-label, non-comparative, multi-centric WINOVER study was reported concerning the patient condition of olmesartan monotherapy \[[@CR51]\]. In this study, 8940 adults patients (\>18 years) with essential hypertension as well as co-morbidities such as angina, diabetes mellitus, or dyslipidemia were recruited. Patients were treated with olmesartan tablet 20 or 40 mg once daily for 6 months. After 3 and 6 months from initiation of treatment with olmesartan, the reduction of systolic blood pressure (SBP) \<140 mmHg and diastolic blood pressure (DBP) \<90 mmHg was observed as primary outcome. As a result, baseline SBP/DBP of 164/100 mmHg was reduced to 153/93, 145/89, 134/84, and 130/82 mmHg at the end of 15 days, 1, 3, and 6 months, respectively, both of which were statistically significant (*p* \< 0.0001). Besides, the consistent increase of percentage of responders for both SBP and DBP from the 15th day to 6 months was observed. The mild-to-moderate AEs rate was 0.08% in all patients, and with no incidence of serious cases. As for the treatment results at 6 months, 96.49% and 96.48% of patients was rated as good when assessed by the treating physicians, respectively, with no severe clinical outcomes occurring. Another similar study was the OLMEBEST study \[[@CR52]\]. This European, multinational, double-blind study also revealed that olmesartan (20 mg tablet) resulted in a mean reduction of 11.8 mmHg in mean sitting diastolic blood pressure and 17.1 mmHg in mean sitting systolic blood pressure from baseline. The adverse event rate was 30.9%, and the majority of these events were mild. It was also highlighted that olmesartan medoxomil 20 mg/day was well tolerated, with no severe clinical outcomes reported.

When compared with candesartan, olmesartan performed more effectively in reducing daytime and 24-h DBP and SBP revealed by Brunner's study \[[@CR53]\]. This randomized, double-blind, parallel-group study included 643 patients aged 19--86 years with mainly mild-to-moderate essential hypertension, which was conducted at 44 centers in Germany, Poland, and the Czech Republic. In the olmesartan group, the result showed that mean decreases by 6.7, 8.4, and 9.3 mmHg from baseline in daytime DBP, after the treating time of week 1, 2, and 8, respectively. The result is superior to the candesartan group (*p* \< 0.0126). The mean 24-h DBP/SBP also showed significant advantages in favor of olmesartan treatment. No severe adverse clinical events occurred.

As for the comparison for other ARBs, Oparil's \[[@CR54]\] study showed that the reduction of sitting cuff DBP with olmesartan (11.5 mmHg) was significantly greater than with losartan, valsartan, and irbesartan (8.2, 7.9, and 9.9 mmHg, respectively). Drug-related AEs and discontinuation were rare among all groups, with no severe adverse events reported. The authors concluded that compared with other ARBs, olmesartan is more effective in reducing cuff DBP in patients with essential hypertension. However, Smith DH's study \[[@CR55]\] suggested that olmesartan was significantly more effective than losartan or valsartan, its effects on mean decrease from baseline in ambulatory blood pressure (ABP) and its goal rates were numerically better.

There were also several studies comparing olmesartan with amlodipine for mild-to-moderate hypertension. Chrysant's study \[[@CR56]\] revealed that though mean reductions in ambulatory and seated BP were similar between the two agents group and both were well tolerated at the recommended starting dose, more patients in the olmesartan group achieved the SBP goal of \<130 mmHg and the DBP goal of \<85 mmHg. This conclusion was also confirmed by Chrysant's further study \[[@CR57]\].

Omboni performed a pooled analysis from two recent identically designed trials \[[@CR58]\]. The two trials compared the head-to-head efficacy and safety of olmesartan and ramipril in elderly patients with essential hypertension with or without metabolic syndrome. After 12 weeks of treatment, BP reductions were greater (*p* \< 0.05) with olmesartan (SBP 17.0 mmHg; 95% CI 18.4, 15.6; DBP 9.6 mmHg; 95% CI 10.4, 8.8) than with ramipril (SBP 14.7 mmHg; 95% CI 16.1, 13.2; DBP 8.4 mmHg; 95% CI 9.2, 7.6) in patients with metabolic syndrome. The BP normalization rates of olmesartan were also greater than ramipril (46.0 vs. 35.8%, *p* \< 0.01) in these patients. The same result also occurred in patients without metabolic syndrome and in the subgroup of patients with valid ABP recordings and metabolic syndrome. As for the drug-related AEs, the proportion of patients was comparable with (olmesartan 2.4 vs. ramipril 2.8%) and without (olmesartan 3.5 vs. ramipril 3.7%) metabolic syndrome. In conclusion, olmesartan provides more effective BP control than ramipril in elderly hypertensive patients with and without metabolic syndrome was made \[[@CR59]\].

Also, some retrospective re-studies compared the efficacy and safety of olmesartan monotherapy with other ARBs, ACEIs, CCBs, diuretics, and β-blockers monotherapy, in which the results revealed that olmesartan showed greater clinical superiority to the other categories above \[[@CR59], [@CR60]\].

### Olmesartan/Amlodipine Versus Amlodipine or Olmesartan {#Sec10}

A randomized, double-blinded clinical trial investigated the efficacy and safety of olmesartan (10 mg/20 mg/40 mg) and amlodipine (5 mg/10 mg) alone and with all possible combinations of variable concentrations \[[@CR61], [@CR62]\]. The primary efficacy variable was the change from baseline in mean sitting diastolic blood pressure (SeDBP) and mean sitting systolic blood pressure (SeSBP) at week 8. The proportion of patients achieving BP targets at week 8 (\<140/90 and \<120/80 mm Hg) was also assessed. The conspicuous features of this study are that all of these efficacy assessments were applied to pre-specified subgroups including race (black and non-black), diabetes status, age (\<65 years, greater than or equal to 65 years) and baseline body mass index (baseline 30 kg/m^2^) and the data were analyzed between sub-groups. According to the results, the reductions of both SeDBP and SeSBP were significant for all olmesartan monotherapy (*p* \< 0.05), amlodipine monotherapy (*p* \< 0.0001) and amlodipine/olmesartan combination therapy (*p* \< 0.0001) regimens by week 8. Specially, the amlodipine/olmesartan combination therapy with dosage of 10 and 40 mg/day achieved the greatest reductions in mean sitting blood pressure in all subgroups except SeSBP in non-Blacks group. As for the safety profiles, the tolerability of subgroups with difficult-to-treat hypertension were similar to their more easily treated counterparts as well as the monotherapy-treated cohorts. Only one serious adverse event (cerebrovascular accident) was reported, occurring in a black, obese female patient aged \<65 years with type II diabetes in the olmesartan medoxomil 20 mg/day group (Table [2](#Tab2){ref-type="table"}).Table 2The different treatment plan regarding olmesartan alone or in combinationCombinations and dosageAuthorsComparatorsTreatment timeSubjectsClinical endpointsBP reductionAchieving rateRates of TEAEsRare drug-related TEAEsReferencesOlmesartan (20 mg)Böhm et al.No12 weeks823 German patients with mild-to-moderate essential hypertensionChange in sitting SBP/DBP and control rate^b^sSBP/sDBP: 20.1/14.9 mmHg at week 1270.0% at week 830.9%No\[[@CR52]\]Olmesartan/amlodipine (40/10 mg)Chrysant et al.Olmesartan (10, 20, 40 mg)/amlodipine (5, 10 mg) combinations and placebo8 weeks1940 patients with difficult-to-treat hypertension^d^Change in seated SBP/DBP and control rate^b^SeSBP/SeDBP: 19.0/30.1 mmHg at week 849.1% at week 829.0%No\[[@CR62]\]Olmesartan/azelnidipine (20/16 mg)Daikuhara et al.Candesartan/amlodipine (8/5 mg)24 weeks300 hypertensive patients complicated with type 2 diabetes mellitus, with 150 person in intervention arm, 150 in comparator armChange in home-measured early morning and clinic-measured blood pressureHome-measured early morning SBP/DBP: 16.7/8.8 mmHg; Clinic-measured SBP/DBP: 15.3/7.1 mmHg at week 24--NoNo\[[@CR71]\]Olmesartan/hydrochlorothiazide (40/25 mg)Chrysant et al.Olmesartan (10, 20, 40 mg)/HCTZ(12.5, 25 mg) combinations and placebo8 weeks502 patients with mean SeDBP of 100--115 mmHgChange in mean seated SBP/DBP and standing SBP/DBP and responder rates^c^SeSBP/SeDBP: 26.8/21.9 mmHg; StSBP/StDBP: 27.7/19.7 mmHg; at week 892.3% at week 8FewNo\[[@CR50]\]Aliskiren/amlodipine (300/10 mg)Axthelm et al.No8 weeks^a^342 patients with stage 2 hypertensionChange in SBP/DBP and normalization rate^b^SBP/DBP: 29.6/19.3 mmHg at week 836.4% at week 8--No\[[@CR72]\]Perindopril/amlodipine (8/10 mg)Ruilope et al.Olmesartan/amlodipine (40/10 mg)24 weeks242 hypertensive patients receiving antihypertensive treatment and the same number in the comparator armChange in central SBP, seated SBP/DBP and BP normalization rate^b^Central SBP: 10.4 mmHg SeSBP/SeDBP: 12.5/5.4 mmHg at week 2457.5% at week 2425.7%Nasopharyngitis 5.8%\
Erectile dysfunction 1.7% Bronchitis 0.8%\[[@CR73]\]Olmesartan/amlodipine/hydrochlorothiazide (40/10/25 mg)Oparil et al.Olmesartan/amlodipine (40/10 mg); olmesartan/HCTZ (40/25 mg); amlodipine/HCTZ (10/25 mg)12 weeks2492 patients aged ≥18 years and mean seated BP (SeBP) ≥140/100 or ≥160/90 mmHgChange in seated SBP/DBP and normalization rate^b^SeSBP/SeDBP: 37.1/21.8 mmHg at week 1269.9% at week 1228.2%1 case of angina pectoris\[[@CR75]\]^a^At the first 4 weeks, patients were given olmesartan/amlodipine (40/10 mg) for therapy; those whose BP were not controlled were switched to aliskiren/amlodipine (300/10 mg) for another 4 weeks of therapy^b^The control/normalization rate is defined by JNC 7-recommended BP goal: \<140/90 mmHg; \<130/80 mmHg for patients with diabetes or CKD or chronic CV disease^c^Defined as an SeDBP \<90 mmHg or a ≥10 mmHg reduction in SeDBP at week 8^d^Patients who were aged ≥18 years with both a mean seated diastolic BP (SeDBP) of 95--120 mmHg from 1 week before randomization and at the randomization visit with a mean SeDBP difference of ≤10 mmHg from the two separate visits

A series of articles have reported that olmesartan/amlodipine combination produced benefits in increasing insulin sensitivity and decreasing inflammatory markers compared to any of them, which can tremendously benefit the hypertensive patients with multiple symptoms \[[@CR63]--[@CR67]\]. Sievers's study found that combined treatment with olmesartan and amlodipine attenuated atherosclerotic lesion progression, possibly due to anti-inflammatory mechanisms, even in advanced atherosclerosis \[[@CR68]\].

### Olmesartan/Azelnidipine Versus Candesartan/Amlodipine {#Sec11}

ARBs and CCBs are often co-administered for treating hypertension. Former studies have revealed that RAS inhibitors (ARB and ACEI) and a CCB effectively decreased central SBP by reducing arterial wave reflection \[[@CR69]\]. Similarly, the J-CORE study by Matsui \[[@CR70]\] has fully demonstrated that compared to the olmesartan (20 mg)/HCTZ (12.5 mg), olmesartan (20 mg)/azelnidipine (16 mg) combination resulted in greater reductions in central SBP and arterial stiffness, although there is no significant difference between the two combinations in 24-h SBP.

To determine which combination performed better, Daikuhara \[[@CR71]\] conducted the OLCA study, which was an open-label randomized study aimed at untreated diabetic hypertensive patients. At the beginning, 300 patients were randomized to have either olmesartan (20 mg/day) or candesartan (8 mg/day), with 150 participants in each group. There were no differences between the two groups. The 115 patients in the olmesartan group and 121 patients in the candesartan group who did not achieve the anti-hypertensive goal (130/80 mmHg) within 12 weeks were assigned to received add-on CCB therapy, treated with azelnidipine 16 mg/day or amlodipine 5 mg/day for 24 weeks. There were similar proportions of patients using insulin or oral antidiabetic drugs in both groups, which did not affect the result of this study. The result showed that no significant difference between the olmesartan and candesartan groups was found in the first 12 weeks. As a result, the olmesartan group achieved greater effect in controlling blood pressure. In the following 24 weeks, mean deduction in clinic-measured SBP/SDP of olmesartan and candesartan group was 15.3 ± 4.8/7.1 ± 3.2 mmHg (both *p* \< 0.01) and 14.5 ± 4.6/6.7 ± 3.1 mmHg (both *p* \< 0.01), respectively. Also, the deduction of early morning BP was 16.7 ± 5.0/8.8 ± 3.0 mmHg (both *p* \< 0.01) and 13.0 ± 4.6/6.4 ± 3.1 mmHg (both *p* \< 0.01). As for the clinical outcome, no severe cases occurred, and none of these patients withdrew due to adverse events. All of these data indicate that both olmesartan and candesartan had good antihypertensive effects, with olmesartan possessing a more significant antihypertensive effect. Furthermore, the olmesartan group achieved significantly greater home-measured early morning BP reduction than the candesartan group (*p* \< 0.05).

### Olmesartan/Amlodipine Versus Aliskiren/Amlodipine {#Sec12}

Axthelm et al. designed a study to investigate the efficacy of aliskiren and amlodipine combination therapy in hypertensive patients whose BP is not adequately controlled by the combination of olmesartan and amlodipine \[[@CR72]\]. This study had two 4-week phases, which were noted as phase 1 and phase 2. Each of these had the treatment protocol of olmesartan 40 mg/amlodipine 10 mg and aliskiren 300 mg/amlodipine 10 mg, respectively. The author switched patients from phase 1 to phase 2, whose BPs were not adequately controlled. Those whose BP was not controlled in phase 2 would be arranged for an optional 4-week combination treatment of aliskiren 300 mg/amlodipine 10 mg/HCTZ 12.5 mg. As a result, 342 patients who were included in phase 1 have a decrease of SBP/DBP by 24.5/14.5 mmHg. In phase 2, 187 patients with uncontrolled hypertension at the end of phase 1 obtained a further SBP/DBP reduction of 5.1 mmHg/4.8 mmHg (95% CI 3.7, 6.5)/(95% CI 3.8, 5.8) with the SBP/DBP responder rates by 44.4%/51.3% and SBP and DBP normalization by 36.4% (*p* \< 0.0001). The 65 patients who received the optional treatment obtained a further decrease of SBP/DBP by 8.1/6.7 mmHg (*p* \< 0.0001). No deaths or severe AEs were reported. In conclusion, the aliskiren/amlodipine and aliskiren/amlodipine/hydrochlorothiazide combination had achieved a clinically and statistically greater reduction in BP when the patient's BP could not be normally controlled by the olmesartan and amlodipine combination.

### Olmesartan/Amlodipine Versus Perindopril/Amlodipine {#Sec13}

The SEVITENSION study compared the effects of perindopril/amlodipine and olmesartan/amlodipine in decreasing central aortic blood pressure \[[@CR73]\]. Six hundred patients were enrolled in this study. At the beginning, the patients received amlodipine 10 mg during a 2--4 weeks run-in, and 486 of them were randomized to receive 24 weeks of double-blind combination treatment, with 244 patients having olmesartan/amlodipine 40/10 mg and 242 patients having perindopril/amlodipine 8/10 mg, with optional hydrochlorothiazide added in patients with inadequate BP control at weeks 4, 8, or 12. The study design is presented in Fig. [3](#Fig3){ref-type="fig"}. The absolute change in central systolic blood pressure (CSBP) from baseline to the final value was set as the primary efficacy variable. As for the result, the CSBP reduction of olmesartan/amlodipine group was higher than perindopril/amlodipine group, with the BP reduced by 14.5 ± 0.83 mmHg versus 10.4 ± 0.84 mmHg. Also, olmesartan/amlodipine recipients achieved significantly greater BP normalization rates than the perindopril/amlodipine recipients (75.6 vs. 57.5%, *p* \< 0.0001). Notably, each treatment was well tolerated, and the proportion of patients with ≥1 drug-related treatment-emergent adverse events (TEAEs) was comparable to the olmesartan/amlodipine (25.0%) and perindopril/amlodipine (25.7%) groups, while the patients that discontinued treatment due to a drug-related TEAE was 5.7% in olmesartan/amlodipine group compared with 7.5% in the perindopril/amlodipine group. No severe clinical outcome was reported. In conclusion, this study strongly suggested that the combination of olmesartan/amlodipine was superior to perindopril/amlodipine in reducing CSBP as well as maintaining a higher rate of BP normalization. The post hoc analysis of this study further also supported the conclusion in hypertensive patients with diabetes \[[@CR74]\].Fig. 3The study design and treatment procedure of the SEVITENSION study \[[@CR73]\]

### Olmesartan/Hydrochlorothiazide Versus Olmesartan or Hydrochlorothiazide {#Sec14}

In a randomized, double-blind, factorial design study \[[@CR50]\], Chrysant investigated the efficacy of olmesartan (10, 20, or 40 mg/day)/hydrochlorothiazide (12.5 or 25 mg/day) with accordingly six possible combination versus each of the agents alone. In total, 502 patients in 12 groups including placebo received their treatment regimens throughout the 8-week experiment. The change in mean trough SeDBP from baseline at week 8 was set as the primary endpoint. The author did not compare BP reductions with different combination doses, which was probably a limitation. The result still suggested that olmesartan/HCTZ led to greater reductions in both SeDBP and SeSBP at week 8 than each of the agents and dosage alone. The reductions of SeSBP/SeDBP in the combined group of olmesartan/HCTZ 20/12.5 mg, olmesartan/HCTZ 40/25 mg, and placebo were 3.3/8.2 mmHg (95% CI 6.0, 10.3)/(95% CI 6.0, 10.3), 20.1/16.4 mmHg (95% CI 17.1, 23.0)/(95% CI 14.7, 18.1), and 26.8/21.9 mmHg (95% CI 22.8, 30.8)/(95% CI 19.5, 24.3), respectively. The result indicated that olmesartan/HCTZ 40/25 mg combination achieved the greatest reduction, and the highest responder rate (92.3%) and control rates (79.5% for diastolic and 87.2% for systolic) were also observed in the olmesartan/HCTZ 40/25 mg/day group. As for drug safety, investigators noted that all dosages of monotherapy and combination therapy were safe and well tolerated, and no significant incidence of treatment-emergent adverse effects was reported. The overall discontinuation rate was 2.0% and was not the result of an AE or related to dosage of any study medication. No severe clinical outcomes were reported.

### Olmesartan/Amlodipine/Hydrochlorothiazide {#Sec15}

It is recommended that patients with uncontrolled hypertension treated with two antihypertensive agents may require a combination of three agents to achieve satisfied BP. Oparil conducted the TRINITY study \[[@CR75]\] to determine whether the triple combination of olmesartan, amlodipine, and HCTZ had better efficacy and safety conditions compared with dual combinations in patients aged ≥18 years who had moderate-to-severe hypertension, who have the SeSBP ≥140/100 or ≥160/90 mmHg. The study design and detail is presented in Fig. [4](#Fig4){ref-type="fig"}. After a 3-week washout period with no study medication and a 12-week double-blind treatment (olmesartan 40 mg/amlodipine 10 mg/HCTZ 25 mg, olmesartan 40 mg/amlodipine 10 mg, olmesartan 40 mg/HCTZ 25 mg, and amlodipine 10 mg/HCTZ 25 mg), the study found that triple combination treatment was associated with significantly greater mean reductions in seated BP compared with the dual combinations. The reduction of SeDBP and SeSBP in triple combination group is 21.8 and 37.1 mmHg, respectively. While in the dual combination group, the SeDBP and SeSBP reductions ranged from 15.1--18.0 mmHg to 27.5--30.0 mmHg (*p* \< 0.001), respectively. As for BP achieving rate, patients in triple combination treatment reached BP targets with significantly higher proportion compared to the dual combinations at week 12 (olmesartan/amlodipine/HCTZ: 69.9%, olmesartan/amlodipine: 52.9%, olmesartan/HCTZ: 53.4%, and amlodipine/HCTZ: 41.1%, respectively \[*p* \< 0.001\]). All of the treatments in this study were generally well tolerated, with 1.5% of patients experiencing serious AEs.Fig. 4Study design of the TRINITY study. *OM* olmesartan medoxomil, *AML* amlodipine besylate, *HCTZ* hydrochlorothiazide \[[@CR75]\]

In the TRINITY ABP sub-study, the authors used the ABP monitoring (ABPM) method to compare the clinical benefits between the same triple combination and the same dual combination, in which they found that the triple combination demonstrated superior efficacy and sustained reductions in ABP compared with its dual-combination components. ABPM is currently recommended by the American Society of Hypertension as the best method for assessing cardiovascular risk in individuals with hypertension \[[@CR76]\]. Therefore, the result supports the idea that triple combination therapy is better than the each of the dual combinations.

Another TRINITY sub-study revealed the fact that triple combination treatment could also benefit patients with different pathological conditions, such as diabetes, chronic kidney disease, and chronic cardiovascular disease \[[@CR56]\]. Factors like age, ethnicity, and race did not affect the treatment results in the triple combination group compared with the dual combination treatment group \[[@CR77]--[@CR80]\].

Safety and tolerability {#Sec16}
-----------------------

Safety and tolerability for oral olmesartan in patients with moderate-to-severe hypertension were continually investigated \[[@CR81], [@CR82]\]. An integrated analysis of efficacy and safety of olmesartan demonstrated that the AEs profile observed with olmesartan monotherapy and combination therapy was approximate to placebo, and dizziness was the only event that occurred more in patients with olmesartan comparing with placebo \[[@CR11]\]. Also, olmesartan was with less AEs compared with valsartan, losartan, and amlodipine during the treatment period. Besides, AEs associated with the combination of olmesartan and HCTZ were generally mild-to-moderate in severity \[[@CR83]\]. The safety of olmesartan/HCTZ was well evaluated in 1243 hypertensive patients. As a result, treatment with olmesartan/HCTZ was well tolerated. Dizziness, flushed face, and upper respiratory tract infections were more often reported in olmesartan/HCTZ recipients than placebo recipients \[[@CR84]\]. However, adverse events were generally mild, transient, and had no relationship with the dose of olmesartan/HCTZ. There was also no difference of AEs between olmesartan/HCTZ and placebo among gender, age, and race groups.

The best-known severe adverse event associated with olmesartan is sprue-like enteropathy, according to several case reports and research articles \[[@CR85]--[@CR90]\]. Rubio-Tapia et al. firstly reported that 22 olmesartan recipients who suffered from chronic diarrhea could recover from the syndrome after stopping olmesartan therapy \[[@CR91]\]. Generally, the symptoms of olmesartan-induced enteropathy are watery diarrhea, abdominal pain, weight loss, and nausea, and symptoms can be ameliorated after stopping the medication. Pathology studies showed clear inflammatory changes in the intestinal mucosa, such as villous blunting with near-complete villous atrophy of the small intestinal mucosa \[[@CR88], [@CR92]--[@CR94]\]. Although the pathogenic mechanism of this disease remains unclear, some hypotheses were presented. Laniro et al. and Rubio-Tapia proposed that a cell-mediated delayed hypersensitivity reaction could be the plausible explanation for these changes \[[@CR95], [@CR96]\]. Another hypothesis suggested that the mechanism of action could involve inhibition of the transforming growth factor beta (TGF-β) pathway leading to a breakdown of the intestinal immune homeostasis, thus causing a pathological variation \[[@CR97]\]. Therefore, early identification of olmesartan-induced enteropathy patients is important, and prompt discontinuation of the medication is strongly recommended \[[@CR98]\].

In addition, combined therapy using olmesartan has been reported to have a positive effect on heart rate variability, which is an independent risk factor in predicting the severity and prognosis of cardiovascular disease. It was also reported that the use of olmesartan had an obvious BP stabilization for elderly recipients, especially in controlling the morning BP surge \[[@CR99]\]. In addition, patients with chronic renal diseases are not suggested to be suitable for combined therapy owing to increased AEs \[[@CR100]\].

Conclusions {#Sec17}
===========

Olmesartan medoxomil, as an angiotensin II receptor antagonist, shows good efficacy in BP reduction and stabilization. When combined with HCTZ or amlodipine, olmesartan has a better effect on controlling BP and reducing the AE rate. In conclusion, olmesartan alone or in combination with other anti-hypertensive agents is effective and well tolerated for the management of hypertension in patients.
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